Cyst fluid biosignature to predict intraductal papillary mucinous neoplasms of the pancreas with high malignant potential

• Verfasst von: Maker, Ajay V. [VerfasserIn]
• Verfasst von: Hu, Vincent [VerfasserIn]
• Verfasst von: Kadkol, Shrihari S. [VerfasserIn]
• Verfasst von: Hong, Lenny [VerfasserIn]
• Verfasst von: Brugge, William [VerfasserIn]
• Verfasst von: Winter, Jordan [VerfasserIn]
• Verfasst von: Yeo, Charles J. [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Büchler, Markus W. [VerfasserIn]
• Verfasst von: Lawlor, Rita T. [VerfasserIn]
• Verfasst von: Salvia, Roberto [VerfasserIn]
• Verfasst von: Scarpa, Aldo [VerfasserIn]
• Verfasst von: Bassi, Claudio [VerfasserIn]
• Verfasst von: Green, Stefan [VerfasserIn]
• Titel: Cyst fluid biosignature to predict intraductal papillary mucinous neoplasms of the pancreas with high malignant potential
• Verf.angabe: Ajay V Maker, MD, FACS, Vincent Hu, PhD, Shrihari S Kadkol, MD, PhD, Lenny Hong, MS,William Brugge, MD, Jordan Winter, MD, FACS, Charles J Yeo, MD, FACS, Thilo Hackert, MD, Markus Büchler, MD, FACS, Rita T Lawlor, PhD, Roberto Salvia, MD, Aldo Scarpa, MD,Claudio Bassi, MD, FACS, Stefan Green, PhD
• E-Jahr: 2019
• Jahr: 19 February 2019
• Umfang: 9 S.
• Fussnoten: Gesehen am 09.09.2019
• Titel Quelle: Enthalten in: American College of SurgeonsJournal of the American College of Surgeons
• Ort Quelle: [Philadelphia, Pa.] : Wolters Kluwer Health, 1997
• Jahr Quelle: 2019
• Band/Heft Quelle: 228(2019), 5, Seite 721-729
• ISSN Quelle: 1879-1190
• DOI: doi:10.1016/j.jamcollsurg.2019.02.040
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1676306552

Abstract

BACKGROUND: Current standard-of-care technologies, such as imaging and cyst fluid analysis, are unable to consistently distinguish intraductal papillary mucinous neoplasms (IPMNs) of the pancreas at high risk of pancreatic cancer from low-risk IPMNs. The objective was to create a single-platform assay to identify IPMNs that are at high risk for malignant progression. - STUDY DESIGN: Building on the Verona International Consensus Conference branch duct IPMN biomarker review, additional protein, cytokine, mucin, DNA, and microRNA cyst fluid targets were identified for creation of a quantitative polymerase chain reaction-based assay. This included messenger RNA markers: ERBB2, GNAS, interleukin 1β, KRAS, MUCs1, 2, 4, 5AC, 7, prostaglandin E2R, PTGER2, prostaglandin E synthase 2, prostaglandin E synthase 1, TP63; microRNA targets: miRs 101, 106b, 10a, 142, 155, 17, 18a, 21, 217, 24, 30a, 342, 532, 92a, and 99b; and GNAS and KRAS mutational analysis. A multi-institutional international collaborative contributed IPMN cyst fluid samples to validate this platform. Cyst fluid gene expression levels were normalized, z-transformed, and used in classification and regression analysis by a support vector machine training algorithm. - RESULTS: From cyst fluids of 59 IPMN patients, principal component analysis confirmed no institutional bias/clustering. Lasso (least absolute shrinkage and selection operator)-penalized logistic regression with binary classification and 5-fold cross-validation used area under the curve as the evaluation criterion to create the optimal signature to discriminate IPMNs as low risk (low/moderate dysplasia) or high risk (high-grade dysplasia/invasive cancer). The most predictive signature was achieved with interleukin 1β, MUC4, and prostaglandin E synthase 2 to accurately discriminate high-risk cysts from low-risk cysts with an area under the curve of up to 0.86 (p = 0.002). - CONCLUSIONS: We have identified a single-platform polymerase chain reaction-based assay of cyst fluid to accurately predict IPMNs with high malignant potential for additional studies.